

Supplementary Information

Rational design of chimeric antisense oligonucleotides on a mixed PO-PS backbone for splice switching applications

Bao T. Le ^{1,2,†}, Suxiang Chen ^{1,3,†} and Rakesh N. Veedu ^{1,2,3*}

¹Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia

²ProGenis Pharmaceuticals Pty Ltd, Bentley, WA, 6102, Australia

³ Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia

*Correspondence: R.Veedu@murdoch.edu.au

† These authors contributed equally

Table S1. The primer sequences and PCR conditions used for the amplification of dystrophin transcripts.

Primary PCR		
Primer set	Ex20Fo	5'-CAGAATTCTGCCAATTGCTGAG-3'
	Ex26Ro	5'-TTCTTCAGCTTGTGTCATCC-3'
PCR conditions	55 °C for 30 min, 94 °C for 2 min before entering 31 cycles of 94 °C for 30 s, 55 °C for 30 s and 68 °C for 90 s	
Secondary PCR		
Primer set	Ex20Fi	5'-CCCAGTCTACCACCCTATCAGAGC-3'
	Ex26Ri	5'-CCTGCCTTTAAGGCTTCCTT-3'
PCR conditions	94 °C for 6 min before entering 33 cycles of 94 °C for 30 s, 55 °C for 1 min and 72 °C for 2 min	






Figure S1. Melting profiles of the ASOs against a synthetic complementary RNA.



Repetition 1



Repetition 2

Figure S2. Original agarose gel images of RT-PCR products (in duplicates).




Figure S3. Original polyacrylamide gel images of the nuclease stability assay.